Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2008 vs Sandostatin LAR in GEP-NET
NCT06505395Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2024
- Primary completion
- Aug 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SYHX2008 in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Progression-free survival at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
SYHX2008
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT06505395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505395.